fashion -WSS

fashion

author：knowledge 2025-09-06 03:56:50 - browse：37

Illustration of a prescription bottle image on the screen of a smart phone – medical tech coverage from STAT — Alex Hogan/STAT

In another sign of the business headwinds facing prescription mental health apps, developer Twill will shop around for a pharmaceutical company to market Aspiro, its cognitive behavioral therapy treatment for both generalized anxiety and major depression.

Twill executives told STAT the company hopes that a drugmaker developing or currently marketing a product for generalized anxiety, or GAD, and major depressive disorder, or MDD, will be interested in adding a digital therapeutic to boost the effect of its drug — as well as its sales. Twill’s chief strategy officer Chris Wasden said that after watching companies built around prescription digital therapeutics, or PDTs, stall out, Twill made the decision earlier this year that it would only take the product to market if it found a willing drugmaker to serve as its partner.

“A PDT is going to be more valuable in the hands of a drug company that has a drug that they would like to get greater adherence [and] greater revenues from rather than trying to get reimbursement for the PDT itself,” he said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Trump surgeon general acknowledges mistakes during Covid

focus

WSS

Stem cell treatment guidelines are released by FDA

AstraZeneca chief proposes a novel edit to the drug pricing bill

Does aspartame cause cancer? What new WHO guidance says

Crinetics acromegaly drug succeeds in late

Listen: Biogen's potential pivot, & Illumina's next chapter

Congress: Eradicate hepatitis C and reduce the deficit

focus

fashion

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Peter Hotez and the public health issue of online harassment

Listen: Biogen's potential pivot, & Illumina's next chapter

Medical leaders decry Supreme Court decision on affirmative action

Grail faces three suits alleging harassment, retaliation

Moonlake's readout produced a cash windfall. Risks remain

Congress: Eradicate hepatitis C and reduce the deficit

BioMarin wins approval for gene therapy to treat hemophilia A

Eli Lilly to acquire Versanis in heated race for weight loss drugs

focus

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Why police arrested suspected Gilgo Beach killer away from his house

Global childhood vaccinations edge closer to pre

The new HIV moral panic

Argenx drug significantly slows progression of nerve disorder

Trump surgeon general acknowledges mistakes during Covid

hotspot

focus

knowledge

entertainment